176787-42-1

Basic information

• Product Name: cyclohexyl (4-nitrophenyl) carbonate
• Synonyms: cyclohexyl (4-nitrophenyl) carbonate;cyclohexyl (4-nitrophenyl) carbonate(WXC03010)
• CAS NO: 176787-42-1
• Molecular Formula: C₁₃H₁₅NO₅
• Molecular Weight: 265.2619
• Mol File: 176787-42-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: cyclohexyl (4-nitrophenyl) carbonate(CAS DataBase Reference)
• NIST Chemistry Reference: cyclohexyl (4-nitrophenyl) carbonate(176787-42-1)
• EPA Substance Registry System: cyclohexyl (4-nitrophenyl) carbonate(176787-42-1)

Safety Data

• Hazardous Substances Data: 176787-42-1(Hazardous Substances Data)

Upstream product

• 7693-46-1 4-Nitrophenyl chloroformate 
• 108-93-0 cyclohexanol 

Relevant articles and documents

Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

The three pan-genotypic HCV NS3/4A protease inhibitors (PIs) currently in clinical use - grazoprevir, glecaprevir, and voxilaprevir - are quinoxaline-based P2-P4 macrocycles and thus exhibit similar resistance profiles. Using our quinoxaline-based P1-P3 m

HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS

The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical comp

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF

The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi

ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL CONTAINING THESE

An arylamidine derivative represented by the general formula (wherein R 1 represents optionally protected or substituted amidino; and R 2 and R 3 are the same or different and each represents hydrogen or halogeno) or a salt of the derivative. The derivati

Bicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, n, and Z are described herein.

PEPTIDIC THROMBIN INHIBITOR COMPOUND

The present invention relates to a novel thrombin inhibitor compound which has a good inhibitory effect against thrombosis and can be orally administered, a process for preparing the same, and to a composition for the therapeutic and/or prophylactic treatment of various diseases associated with thrombin inhibition mechanism, which comprises the same as an active ingredient.

N-acylamino acid amide compounds and intermediates for preparation thereof

The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.

A novel intramolecular decarboxylative glycosylation via mixed carbonate

A two-step glycosylation procedure, which involves (1) linking two sugars by using carbonate as a connector, (2) removing carbon dioxide to form a glycosidic bond by the aid of Lewis acid, has been developed. This glycosylation procedure was based on the opposite mode of connection, where a glycosyl acceptor was activated to link sugars.